Drug Database
RI

risperidone + trihexyphenidyl hydrochloride (Relivon Forte / Relivon Plus)

✓ Approved

A. N. Pharmacia Laboratories · DRD2 · Small Molecule

What is risperidone + trihexyphenidyl hydrochloride?

risperidone + trihexyphenidyl hydrochloride is a small molecule developed by A. N. Pharmacia Laboratories. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesRelivon Forte, Relivon Plus
CompanyA. N. Pharmacia Laboratories
Drug ClassSmall Molecule
Molecular TargetDRD2, HTR2A
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, A. N. Pharmacia Laboratories

Mechanism of Action

Molecular Targets

risperidone + trihexyphenidyl hydrochloride acts on 2 molecular targets:

DRD2dopamine receptor D2 (D2DR, D2R)
HTR2A5-hydroxytryptamine receptor 2A (5-HT2A, HTR2)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

risperidone + trihexyphenidyl hydrochloride is developed for 3 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Psychiatric disordersSchizophrenia✓ Approved
Psychiatric disordersBipolar disorder✓ Approved
Psychiatric disordersAutism spectrum disorder✓ Approved

Related Research Articles

PubMedZhonghua nan ke xue = National journal of andrology2026-11-11

[Effect of esketamine on anesthesia and postoperative analgesia in patients with prostate resection: Based on oxidative stress response].

Liu Dapeng D, Feng Lingling L, Yao Qun Q, Li Jianwei J et al.

Objective To investigate the effects of esketamine on postoperative analgesia, cognitive function, oxidative stress and safety in patients with electroprostatectomy. Methods One hundred and twenty patients who underwent electroprostatectomy in Zaozhuang Municipal Hospital from October 2021 to May 2022 were selected and divided into experimental group and control group according to the different treatment, with 60 cases in each group. The patients in control group were treated with routine sufentanil during the operation. And esketamine hydrochloride was used in the experimental group at the dosage of 0.2 mg/kg 10 minutes before the end of the operation. VAS score and MMSE score were recorded at 0.5, 2, 4 and 12 h after surgery. The levels of oxidative stress indexes including NE and GSH-Px were compared between the two groups, and the postoperative urinary tract irritation and adverse reactions were analyzed. Results There was significant difference in VAS score between the two groups at 0.5 h and 2 h after surgery (P<0.05), but no significant difference at 4 h and 12 h (P>0.05). There was significant difference in MMSE score at 0.5 h after operation (P<0.05). The scores of urethral irritation in the experimental group were significantly lower than those in the control group at 0.5 h and 2 h after operation (P<0.05), and the inhibition effect on urethral irritation was significant. After anesthesia, the levels of NE and GSH-Px in experimental group showed a more dramatic improvement compared to control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Esketamine has good postoperative analgesic effect in elderly patients undergoing transurethral resection of prostate with a temporary effect on early postoperative cognitive function, which alleviates symptoms of urinary duct irritation and oxidative stress caused by surgery.

PMID 43012260
Read full article →
PubMedZhonghua nan ke xue = National journal of andrology2026-11-11

[Clinical efficacy and mechanism of Liniao Tonglin decoction in treating UU-infected oligoasthenospermia with dampness-heat pouring down syndrome].

Zhu Fanyu F, Li Ninghua N, Yang Wentao W

Objective To explore the clinical effect and mechanism of Liniao Tonglin decoction on oligoasthenospermia caused by Ureaplasma urealyticum (UU) infection with dampness-heat pouring down syndrome. Methods Eighty-eight patients were randomly divided into control group and observation group, with 44 cases in each group. The patients in control group were treated with doxycycline hydrochloride enteric-coated capsules and doxycycline tablets. While the patients in observation group were treated with Liniao Tonglin decoction on the basis of the treatment given to the control group. Both groups were treated for 14 days. Sperm concentration, total sperm count, progressive motility sperm rate(PR%), sperm motility rate（［PR+NP］%）, seminal plasmic elastase, interleukin-6(IL-6), interleukin-17(IL-17) levels TCM syndrome score and negative conversion rate of UU were compared between the two groups before and after the treatment. Results The overall efficacy rate of the observation group was significantly higher than that in the control group (86.05% vs 66.67% , χ2=4.435, P<0.05). UU negative conversion rate was also superior in the observation group (95.35% vs 88.10%，P>0.05). The increases in sperm concentration, total count, PR%, and （PR+NP）% (P<0.05) exhibited in both of two groups after the treatment, with significantly greater improvements in the observation group (P<0.05). The levels of seminal elastase, IL-6, IL-17 and TCM syndrome scores declined in both groups (P<0.05), with greater improvements in the observation group as well (P<0.05). Conclusion Liniao Tonglin decoction combined with antibiotics improves the count and motility of sperm and TCM syndrome score of oligoasthenospermia induced by UU infection with dampness-heat pouring down syndrome, increases the negative rate of UU, inhibits the expression of inflammatory factors, and changes the patency of reproductive tract and the living environment of sperm.

PMID 43012219
Read full article →
PubMedZhonghua zhong liu za zhi [Chinese journal of oncology]2026-11-11

[Mitoxantrone hydrochloride liposomes combined with R-GDP regimen in the treatment of relapsed/refractory diffuse large B-cell lymphoma: a single-arm, multicenter, exploratory clinical study].

Ma L L, Zhao J J, Wang J R JR, Zheng M J MJ et al.

Objective: To evaluate the efficacy and safety of the mitoxantrone liposome combined with R-GDP regimen (R-GDP-Mito regimen) in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Methods: From May 2023 to September 2025, a total of 33 patients with relapsed/refractory DLBCL(R/R DLBCL) were enrolled from multiple centers, including Shanxi Provincial Cancer Hospital, Jincheng People's Hospital of Shanxi Province, Heping Hospital Affiliated to Changzhi Medical College, and Datong Second People's Hospital of Shanxi Province. All patients received 2 to 6 cycles of the R-GDP-Mito regimen. The short-term and long-term efficacy as well as adverse events were analyzed. Results: Among the 33 patients, 16 achieved complete remission (CR), 11 achieved partial remission (PR), 3 had stable disease (SD), and 3 experienced disease progression (PD). The objective response rate (ORR) was 81.8% (27/33), with a 95% CI of 61.4% to 92.3%. The median time to best response was 1.9 months. With a median follow-up of 4.8 months, disease progression was observed in 4 patients, and 5 patient deaths were recorded, attributed to disease progression and severe pulmonary infection, respectively. The median progression-free survival (PFS) was not reached, while the median overall survival (OS) was 16.1 months. The 1-year PFS and OS rates were 56.6% and 90.5%, respectively. All 33 patients experienced adverse events (AEs). Hematological AEs occurred in 60.6% (20/33) of patients, and non-hematological AEs occurred in 81.8% (27/33) of them. Conclusion: The R-GDP-Mitoregimen demonstrates high antitumor activity and well-controlled safety profile in R/R-DLBCL patients, offering a promising new therapeutic option, particularly for those unable to immediately access or tolerate novel targeted or immunotherapy regimens.

PMID 43010748
Read full article →
PubMedFrontiers in psychiatry2026-11-10

Comparative efficacy and safety of quetiapine versus other atypical antipsychotics for behavioral and psychological symptoms in Alzheimer's disease: a systematic review and meta-analysis.

Wang Jun J, Chen Wanyue W, Zhang Zhihua Z

The management of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease (AD) remains a significant challenge. While atypical antipsychotics are used, their comparative efficacy and safety, particularly for quetiapine, are not well-established within a homogeneous AD population. This meta-analysis aimed to directly compare the efficacy and safety of quetiapine versus other active pharmacological agents (primarily risperidone and olanzapine) for BPSD specifically in patients with AD. A systematic search of PubMed, Embase, Cochrane Library, Web of Science, CNKI, and WanFang databases was conducted up to March 15, 2024, for randomized controlled trials (RCTs). The primary efficacy outcome was treatment failure (lack of clinical improvement). Safety outcomes included specific adverse events. Data were pooled using random-effects models to calculate odds ratios (ORs) with 95% confidence intervals (CIs). Twenty-five RCTs involving 2143 participants were included. The pooled analysis of 16 studies (n=1384) demonstrated that quetiapine was associated with significantly lower odds of treatment failure compared to other atypical antipsychotics (OR 0.66, 95% CI 0.49 to 0.89, P = 0.006). In pre-specified subgroup analyses, quetiapine showed significant superiority over risperidone (OR 0.50, 95% CI 0.33 to 0.75, P = 0.0009) and a non-significant trend favoring quetiapine over olanzapine (OR 0.90, 95% CI 0.58 to 1.38, P = 0.62). Regarding safety, quetiapine was associated with a substantially and significantly lower risk of extrapyramidal symptoms (EPS) (OR 0.17, 95% CI 0.09 to 0.33, P<0.00001). No significant differences were found for other common adverse events such as somnolence, dizziness, or constipation. This meta-analysis suggests that quetiapine may offer a potential efficacy advantage for alleviating BPSD in patients with AD, particularly when compared to risperidone, while demonstrating comparable overall effectiveness to other atypicals. Its most distinguishing feature is a substantially lower risk of extrapyramidal symptoms. Interpretation of these findings must be tempered by the moderate risk of bias in constituent trials, the necessary harmonization of disparate efficacy metrics, and the scarcity of long-term safety data. Quetiapine may serve as a neurologically better-tolerated option when non-pharmacological strategies are insufficient, pending careful, time-limited use.

PMID 43005608
Read full article →
PubMedCureus2026-11-10

Severe Motor Deterioration of Young-Onset Parkinson's Disease in Pregnancy Following Medication Rationalisation: A Case Report.

Naing Ei Ei P EEP, Ko Ko Naw Phu N NPN, Phyu Mya K MK

Parkinson's disease (PD) in pregnancy is rare, and there are no agreed guidelines for its management. We report a 34-year-old primigravida with a three-year history of young-onset PD who presented at eight weeks' gestation with an unplanned pregnancy. She had previously tolerated levodopa poorly, with nausea and early peak-dose dyskinesia, and before conception her symptoms were reasonably controlled on amantadine, selegiline and procyclidine. Because of the potential teratogenicity of amantadine and limited safety data for the other agents, her treatment was changed to co-careldopa (carbidopa/levodopa) with domperidone. Her condition deteriorated soon after the switch. Despite stepwise increases in levodopa to 400-450 mg/day, by 31 weeks she was wheelchair-dependent, with severe peak-dose dyskinesia alternating with "off" periods and freezing, and she relied on her husband for feeding and personal care. Other drug options and deep brain stimulation were deferred until after delivery. Her care involved neurology, obstetric medicine, obstetric anaesthesia, safeguarding midwives, physiotherapy and occupational therapy, and she received thromboprophylaxis for immobility. She presented in spontaneous labour at 37+5 weeks and underwent a category 2 caesarean section under general anaesthesia, as constant tremor precluded neuraxial anaesthesia. Estimated blood loss was 750 mL. Her daughter had Apgar scores of 4, 7 and 9 at 1, 5 and 10 minutes, respectively, and weighed 2250 g (3.4th centile). Postpartum, dyskinesia and tremor temporarily prevented her from holding her baby, and trihexyphenidyl was started; her symptoms were unchanged five weeks after delivery. In young-onset PD, withdrawal of an effective pre-pregnancy regimen may be followed by significant functional decline, and previous levodopa intolerance may be a warning sign. This case highlights the importance of pre-conception counselling, early multidisciplinary planning and postnatal support.

PMID 43006005
Read full article →
PubMedChemphyschem : a European journal of chemical physics and physical chemistry2026-11-10

Interconversion Among Different Forms of Lumichrome in Aqueous Pluronic P84 Solutions: Effects of Glucose, Urea, and Guanidine Hydrochloride.

Giri Suman Kalyan SK, Manna Sagar Kumar SK, Seth Debabrata D

This work represents a detailed photophysical investigation of Lumichrome (LuC) in a hydrophobic triblock copolymer, Pluronic P84, as a function of the kosmotropic osmolyte, glucose, and the chaotropic osmolytes, urea and guanidine hydrochloride (GH). The spectral characteristics of LuC demonstrate that, addition of glucose lowers the critical micelle temperature (CMT) of P84, suggesting that dehydration of poly (propylene oxide) (PPO) blocks of P84 through the "sugaring-out" phenomena promotes micellization. In contrast, urea and GH increase the CMT of P84, indicating enhanced polymer hydration and weakened hydrophobic interactions that hinder micellization. Fluorescence spectra of LuC illustrate that osmolytes and temperature modulate the microenvironment of LuC. This was confirmed by finding different forms of LuC in P84 micelles with help of steady state and time resolved fluorescence emission studies. The emission spectrum shows a blueshift as temperature increases. The addition of glucose produced no significant shift in the dominant ~460 nm emission band, while additional emission features/shoulders appeared around ~530 and ~436 nm. Fluorescence lifetime data suggest that, along with 7,8-dimethylalloxazine (DMAL) form, A10, A3 and 7,8-dimethylisoalloxazine (DMIS) species of LuC may also exist within the P84 micelle. Fluorescence anisotropy measurements revealed distinct osmolyte-dependent rotational dynamics, indicating changes in the microenvironment surrounding LuC.

PMID 43004135
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about risperidone + trihexyphenidyl hydrochloride